We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Notable Notes |

Tumor Necrosis Factor and the Tenacious α

Øystein Grimstad, MD, PhD1
[+] Author Affiliations
1Department of Dermatology, University Hospital in North Norway, Tromsø, Norway
JAMA Dermatol. 2016;152(5):557. doi:10.1001/jamadermatol.2015.4322.
Text Size: A A A
Published online


Tumor necrosis factor (TNF) is a central cytokine in inflammation and an important therapeutic target in dermatology. For reasons unknown, TNF is still referred to as TNF-α in numerous newly published scientific papers, almost 2 decades after the cytokine was renamed. Of notice, this transgression is common in biomedical science, not limited to dermatology.

In 1975, Carswell and colleagues1 identified TNF from human serum as responsible for necrosis in different tumors in mice. Demonstration of functional and sequential homology of TNF and the previously discovered cytotoxic factor lymphotoxin in 1985 resulted in renaming of TNF as TNF-α and lymphotoxin as TNF-β.2 These 2 cytokines laid the foundation for the isolation and identification of the larger family of cytokines, now known as the TNF superfamily. In 1993, a close homologue of lymphotoxin, the lymphotoxin-β, was discovered.3 Subsequently, at the Seventh International TNF Congress (May 17-21, 1998; Hyannis, Massachusetts), the name “TNF-β” was changed to “lymphotoxin-α.” Concurrently, “TNF-α” became an orphan term with no meaning different from the original term, “TNF,” which was reinstated as official name of the cytokine.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections